possible. 31. 2023
Appointments include world-renowned bioinformatics expert Professor Charlotte Deane and veterans of drug development and FDA approvals, including Drs. Eric Rovinsky
BOSTON--( BUSINESS WIRE )--AI Proteins, Inc., a growing biotechnology company harnessing the power of computingOne more timeProtein Design for the development of new therapeutic mini proteins announced today the formation of a Scientific Advisory Committee. The board will provide deep industry insight and knowledge to accelerate the company's efforts to bring next-generation therapies to market.
The eight-member panel includes: Alice Bexon, MD; Charlotte Dean, MD; Todd Fehniger, MD, PhD; Justin Gainor, MD; Dennis Klinman, MD, PhD; Ph.D., Ph.D. Eric Rowinsky, MD; and Omer Yilmaz, MD.
"I am thrilled to welcome this incredible team of physicians and scientists," said Chris Bahl, Founder, President and CSO of AI Proteins. "We are excited by the depth and breadth of experience this exceptional team brings to AI Proteins and believe their guidance will be invaluable in advancing our mission to develop new medicines based on tiny proteins to help patients as as quickly as possible."
AI Proteins has built a high-throughput drug discovery platform that enables companies to develop and optimize therapeutic proteins at unprecedented speed to treat a variety of diseases. The Scientific Advisory Committee will provide important guidance in the selection of therapeutic candidates for further development.
Among those on the newly formed board is Professor Charlotte Deane MBE, one of the world's leading experts in structural bioinformatics. In her current role as Chief Scientific Officer, Artificial Intelligence at Exscientia, she focuses on artificial intelligence, machine learning and protein design and discovery. AI Proteins appreciates the opportunity to work with Professor Deane, who has done excellent work in this area and will bring a fresh perspective to the company.
"I am excited by the unique way AI Proteins uses computational precision combined with artificial intelligence to engineer tiny proteins that target specific disease profiles and challenges," said Professor Deane. “through useOne more timeThe design of AI Proteins allows for a high level of control over the function and properties of each protein, enabling the development of therapies that more effectively address unmet medical needs. "
The FDA drug approval process will play an important role in how companies advance drug candidates. For this reason, AI Proteins sought Scientific Advisory Board members who are familiar with clinical development, securing FDA approval, and have a deep understanding of the many complexities involved.
Dr. Eric Rowinsky has spent years developing cancer treatments and preparing molecules for FDA approval. He held leadership positions at Hummingbird Bioscience, Inspirna (formerly Rgenix), Stemline Therapeutics and Imclone Systems. Dr. Rowinsky was also an associate professor of medicine at New York University School of Medicine. "FDA approval of new drugs is notoriously complex, and rightfully so," said Dr. Rovinsky. "The FDA wants to ensure the efficacy and safety of every drug it brings to market, and I look forward to helping AI Proteins demonstrate the tremendous potential for its tiny protein therapeutics because it has its first products to bring to clinic.
About the AI protein
Boston-based AI Proteins is a biotechnology company on a mission to reinvent protein therapeutics by rethinking how entirely new proteins are developed. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of low-cost, long-lasting and highly specific proteins with oral potential. In addition, the AI Proteins platform can significantly accelerate the development of lead therapeutic candidates ready for IND-triggering studies. For more information, visitaiproteins.com - Website.
AI Protein Scientific Advisory Board
Alice Bexon, MD
Dr. Alice Bexon is an experienced pharmaceutical and biotechnology industry professional with over 20 years of experience. As the founder of Bexon Clinical Consulting, she advises various organizations and has extensive knowledge of clinical development, medical marketing and regulatory interactions.
Dr. Charlotte Dean
Prof. Charlotte Deane MBE, Distinguished Scientist, Professor of Structural Bioinformatics at the University of Oxford. As a Fellow of St. Anne and Chief Scientific Officer of Exscientia - Artificial Intelligence, her research focuses on protein structure, interaction networks and applications of theoretical and empirical analysis. With expertise in structural modeling, bioinformatics and library design, her valuable insights contribute to the advancement of machine learning algorithms in this field.
Todd Fehniger, MD, Ph.D.
Dr. Todd Fehniger is an experienced physician and scientist specializing in immunology and oncology. He is currently a Professor of Medicine at the University of Washington School of Medicine, leading research groups focused on understanding NK cell development, enhancing the immune response to cancer, and immunogenomics of lymphoma. Dr. Fehniger has a strong background in both basic and clinical research with interests in hematologic malignancies, hematopoietic cell transplantation, and cellular immunotherapy.
Justin Gaynor, MD
Dr. Justin Gainor is a prominent figure in the field of breast cancer and Director of the Breast Cancer Program Center at Massachusetts General Hospital. His research focuses on targeted therapy and immunotherapy, with a particular focus on oncogene-associated lung cancers, including those involving oncogene ALK and RET fusions. Dr. Gainor directs clinical trials investigating new targeted therapies and has been instrumental in understanding the mechanisms of resistance to these therapies.
Dennis Klinman, MD
Dr. Dennis Klinman is currently the Chief Scientific Advisor of COBRO VENTURES, INC. He is trained in rheumatology and immunology. He spent 18 years with the FDA before joining the NCI, where he served as chief investigator for 14 years. He holds several key patents in the areas of TLR agonists and adjuvants for Heplisav (hepatitis B vaccine) and the latest generation of anthrax vaccines. His areas of expertise include immunotherapy, cancer vaccines, innate immunity, TLR agonists, autoimmunity and regulatory affairs.
Carl Novina, MD, PhD
Dr. Carl Novina is an accomplished researcher with a diverse academic background and co-founder of several companies, including AI Proteins, NextRNA Therapeutics, Dynamic Cell Therapies, and Microbial Machines. He is currently a principal investigator at the Dana-Farber Cancer Institute and an associate professor at Harvard Medical School. His research focuses on cancer immunology and virology, using innovative technologies to bridge the gap between biological discovery and the development of new therapies.
Eric Rowinsky, MD
Dr. Eric Rowinsky is an accomplished and experienced physician with extensive experience in the biopharmaceutical industry. He has held various academic and management positions, including at Hummingbird BioScience, Inspirna (formerly Rgenix), Stemline Therapeutics, and ImClone Systems. Dr. Rowinsky has played a key role in the development and FDA approval of multiple cancer therapies. With an extensive background in medical oncology, he has made significant contributions to the field through clinical and preclinical research, served as an adjunct professor at New York University School of Medicine, and served as an adjunct professor at Biogen Inc., Fortress Biotech. Purple Bio and Verastem Inc.
Omer Yilmaz, MD, PhD
Dr. Omer Yilmaz is a distinguished professor and pathologist focused on understanding the effects of different diets on adult stem cells and their microenvironment on tissue regeneration, aging and carcinogenesis. He is currently the Eisen and Chang Professor of Development, Associate Professor of Biology at MIT, and Board Certified Anatomic Pathologist at Massachusetts General Hospital. His laboratory has developed innovative technologies such as genetically defined colon cancer organoids and endoscopic Crispr/Cas9 genome editing to study tumorigenesis, growth, senescence, metastasis, immunity related to different nutritional states and microbiomes of the intestine. surveillance and drug resistance.
interlocutor
media
Ben Kellogg
Bunsen
ben@bunsenstudio.com
+1 (917) 816-0831